紫杉醇联合洛铂腹腔灌注化疗治疗复发性卵巢癌的临床观察  

Clinical observation of paclitaxel combined with intraperitoneal chemotherapy with lobaplatin in treatment of recurrent ovarian cancer

作　　者：瞿媛媛[1] QU Yuan-yuan(Department of Oncology,the Second Hospital of Wuhan Iron and Steel（Group）Corporation,Hubei 430085,China)

机构地区：[1]武汉钢铁(集团)公司第二职工医院肿瘤科,湖北430085

出　　处：《中国临床新医学》2018年第6期558-560,共3页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：目的观察紫杉醇联合洛铂腹腔灌注化疗治疗复发性卵巢癌的疗效和毒性反应。方法选择28例复发性卵巢癌患者,采用紫杉醇联合洛铂腹腔灌注方案化疗,紫杉醇135 mg/m2静脉滴注d1+洛铂50 mg腹腔灌注d2,每3周为一个周期,完成4个周期后观察疗效及毒副反应。结果紫杉醇联合洛铂腹腔灌注对复发性卵巢癌效果较好,病灶控制率为82.1%,腹水控制率为87.5%,CA125下降率为85.7%,其主要不良反应为骨髓抑制、消化道反应、周围神经毒性,对症治疗后患者均可耐受。结论紫杉醇联合洛铂腹腔灌注治疗复发性卵巢癌安全、有效,值得临床进一步推广和应用。Objective To observe the efficacy and toxicity of paclitaxel combined with lobaplatin intraperitoneal chemotherapy in treatment of recurrent ovarian cancer. Methods 28 patients with recurrent ovarian cancer were treated with paclitaxel combined with intraperitoneal perfusion chemotherapy with lobaplatin,paclitaxel 135 mg/m^2 ivgtt d1 ＋ lobaplatin 50 mg/m2 ip d2,every 3 weeks for a cycle. The curative effect and adverse reactions were observed after the completion of 4 cycles. Results Paclitaxel plus lobaplatin intraperitoneal chemotherapy had better effectiveness for treatment of recurrent ovarian cancer. The lesion control rate,the ascites control rate and the CA125 reduction rate were 82. 1%,87. 5% and 85. 7% respectively. The main adverse reactions were bone marrow suppression,gastrointestinal reactions and neurotoxicity. The patients were tolerable after symptomatic treatment. Conclusion Paclitaxel combined with lobaplatin intraperitoneal chemotherapy is safe and effective in treatment of recurrent ovarian cancer.

关 键 词：复发性卵巢癌 紫杉醇 洛铂 腹腔灌注 化疗 

分 类 号：R737.31[医药卫生—肿瘤]